Patents by Inventor Sean Chadwick

Sean Chadwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Single nucleotide polymorphisms and community-associated methicillin-resistant
    Patent number: 10829826
    Abstract: The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: November 10, 2020
    Inventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
  • Novel Single Nucleotide Polymorphisms and Community-Associated Methicillin-Resistant Staphylococcus aureus
    Publication number: 20190177772
    Abstract: The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.
    Type: Application
    Filed: February 21, 2019
    Publication date: June 13, 2019
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
  • Single nucleotide polymorphisms and community-associated methicillin-resistant
    Patent number: 10221462
    Abstract: The present invention is based on the discovery of polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: March 5, 2019
    Assignee: Medical Diagnostic Laboratories, LLC.
    Inventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
  • Novel Single Nucleotide Polymorphisms and Community-Associated Methicillin-Resistant Staphylococcus aureus
    Publication number: 20170314065
    Abstract: The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 2, 2017
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
  • Single nucleotide polymorphisms and community-associated methicillin-resistant
    Patent number: 9738938
    Abstract: The present invention is based on the discovery of polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: August 22, 2017
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
  • Novel single nucleotide polymorphisms and community-associated methicillin-resistant staphylococcus aureus
    Publication number: 20120009572
    Abstract: The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.
    Type: Application
    Filed: May 9, 2011
    Publication date: January 12, 2012
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai